Liquidia Co. (NASDAQ:LQDA) Shares Purchased by Whitefort Capital Management LP

Whitefort Capital Management LP boosted its position in Liquidia Co. (NASDAQ:LQDA - Free Report) by 16.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,987,245 shares of the company's stock after acquiring an additional 285,220 shares during the quarter. Liquidia accounts for 11.2% of Whitefort Capital Management LP's investment portfolio, making the stock its 3rd biggest position. Whitefort Capital Management LP owned 2.35% of Liquidia worth $23,370,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in LQDA. LM Advisors LLC purchased a new position in Liquidia in the fourth quarter valued at about $25,948,000. Invesco Ltd. raised its position in Liquidia by 2,675.0% in the fourth quarter. Invesco Ltd. now owns 700,171 shares of the company's stock valued at $8,234,000 after purchasing an additional 674,940 shares during the period. Janus Henderson Group PLC raised its position in Liquidia by 1,484.5% in the fourth quarter. Janus Henderson Group PLC now owns 535,552 shares of the company's stock valued at $6,293,000 after purchasing an additional 501,752 shares during the period. Mirabella Financial Services LLP purchased a new position in Liquidia in the fourth quarter valued at about $5,880,000. Finally, Eversept Partners LP raised its position in Liquidia by 314.1% in the fourth quarter. Eversept Partners LP now owns 571,305 shares of the company's stock valued at $6,719,000 after purchasing an additional 433,356 shares during the period. Institutional investors and hedge funds own 64.54% of the company's stock.

Liquidia Stock Down 1.3%

Shares of NASDAQ:LQDA traded down $0.21 during trading on Friday, hitting $15.35. 4,742,122 shares of the company traded hands, compared to its average volume of 1,067,235. The stock has a market capitalization of $1.31 billion, a price-to-earnings ratio of -9.42 and a beta of 0.24. The business's fifty day moving average is $14.74 and its 200-day moving average is $13.59. Liquidia Co. has a one year low of $8.26 and a one year high of $19.41.

Liquidia (NASDAQ:LQDA - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.03). The company had revenue of $3.12 million for the quarter, compared to the consensus estimate of $3.23 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. On average, analysts forecast that Liquidia Co. will post -1.51 EPS for the current year.

Insider Activity

In other Liquidia news, insider Jason Adair sold 1,856 shares of the company's stock in a transaction on Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $25,185.92. Following the transaction, the insider now owns 184,304 shares of the company's stock, valued at approximately $2,501,005.28. This represents a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Rajeev Saggar sold 2,450 shares of the business's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $13.67, for a total transaction of $33,491.50. Following the sale, the insider now directly owns 263,152 shares in the company, valued at approximately $3,597,287.84. This trade represents a 0.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 33,138 shares of company stock valued at $450,233. 26.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on LQDA. Oppenheimer set a $13.00 target price on Liquidia and gave the stock an "underperform" rating in a research report on Monday, May 19th. Scotiabank reaffirmed an "outperform" rating on shares of Liquidia in a research report on Monday, May 5th. Needham & Company LLC reaffirmed a "buy" rating and set a $25.00 target price on shares of Liquidia in a research report on Wednesday. HC Wainwright reaffirmed a "buy" rating and set a $29.00 target price on shares of Liquidia in a research report on Monday, May 12th. Finally, Wall Street Zen raised Liquidia from a "sell" rating to a "hold" rating in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Liquidia currently has an average rating of "Moderate Buy" and a consensus target price of $25.56.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).